Inmune Bio Inc. (INMB)
NASDAQ · Healthcare
Inmune Bio Inc. Operating Income 2017–2025
Inmune Bio Inc. annual/quarterly operating income history and growth rate from 2017 to 2025. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Inmune Bio Inc. operating income for the quarter ending March 31, 2025 was -9.9 M, a 10.09% decrease year-over-year.
- Inmune Bio Inc. operating income for the twelve months ending March 31, 2025 was -35.9 M, a 34.15% increase year-over-year.
- Inmune Bio Inc. annual operating income for 2025 was -47.4 M, a 11.14% increase from 2024.
- Inmune Bio Inc. annual operating income for 2024 was -42.6 M, a 43.35% increase from 2023.
- Inmune Bio Inc. annual operating income for 2023 was -29.7 M, a 14.60% increase from 2022.
- Inmune Bio Inc. annual operating income for 2022 was -26.0 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Inmune Bio Inc. Operating Income — FAQ
Inmune Bio Inc. (INMB) operating income over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
What is Inmune Bio Inc.'s operating income?
Inmune Bio Inc. (INMB) reported operating income of -$47M for fiscal 2025.
Where can I see INMB's operating income history?
The chart and table above show Inmune Bio Inc.'s operating income by year and by quarter, including the growth rate.